Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

215,101-215,130 of 319,975

filter-aware
34
Includes three distinct charts: a dot plot for IC50, a bar chart for selectivity index, and a bar chart for brain penetrance.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
Nuvalent | Investor Presentation Deck | 39 slidesNuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
36
The slide uses a cascading hexagonal process flow to illustrate the methodology.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
37
The slide uses a timeline-style layout to track drug development progress from discovery through clinical phases.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
38
Includes a molecular structure visualization.Nuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
39
Nuvalent | Investor Presentation Deck | 39 slidesNuvalent | Investor Presentation Deck | 39 slides · Nuvalent
Pitch deck Investor relations 1 hit
01
Slide 1
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
02
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
03
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
04
The slide uses a visual association between the three executives and the logos of companies/products they have been associated with.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · Team1 hit
05
The slide uses a timeline-style layout to represent drug development stages.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
06
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
07
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
08
Includes a molecular pathway diagram and a Western blot image as evidence.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
09
The slide demonstrates superior tumor volume reduction by NXP800 compared to standard-of-care Cisplatin in both SKOV-3 and TOV-21G models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
10
Includes a patient-derived xenograft (PDX) study workflow diagram and a tumor volume growth curve.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The chart shows tumor volume reduction over 28 days compared to vehicle control.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
12
Clinical trial NCT05226507 status update.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
13
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
14
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
15
The visualization is a standard kinome tree map used in pharmaceutical research to demonstrate drug selectivity.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
16
Uses a structural biology diagram to illustrate mechanism of action.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
17
Includes a biological pathway diagram, microscopy images, and an IC50 dose-response curve.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
18
The charts demonstrate efficacy in specific cell lines (KYSE70 and Cal27) with known genetic alterations.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
19
Includes two distinct experimental setups: cell proliferation assays and mouse tumor growth models.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
20
Clinical trial identifier NCT05873686 is provided.Nuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
21
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
22
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
23
Nuvectis Pharma | Investor Presentation Deck | 23 slidesNuvectis Pharma | Investor Presentation Deck | 23 slides · Nuvectis Pharma
Pitch deck Investor relations 1 hit
01
Slide 1
Nuwellis | Investor Presentation Deck | 29 slidesNuwellis | Investor Presentation Deck | 29 slides · Nuwellis
Pitch deck Investor relations 1 hit